About Liprin-alpha-4
Liprin-alpha-4 (PPFIA4) is a protein
from Homo sapiens identified by UniProt accession
O75335, 1185 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Liprin-alpha-4 |
|---|
| UniProt accession | O75335 |
|---|
| Gene | PPFIA4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1185 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (71)
Diseases linked to this target (Open Targets).
- atrial fibrillation · score 0.35
- neurodegenerative disease · score 0.33
- cardiac arrhythmia · score 0.28
- atrial flutter · score 0.27
- cardiac edema · score 0.22
- chronic obstructive pulmonary disease · score 0.21
- cardiac troponin T measurement · score 0.17
- cutaneous melanoma · score 0.17
- squamous cell lung carcinoma · score 0.16
- head and neck squamous cell carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75335-F1 | alphafold | PREDICTED | 65.73 | — |
Amino-acid sequence (1185 residues)
MCEVMPTINE GDRLGPPHGA DADANFEQLM VNMLDEREKL LESLRESQET LAATQSRLQD AIHERDQLQR HLNSALPQEF ATLTRELSMC REQLLEREEE ISELKAERNN TRLLLEHLEC LVSRHERSLR MTVVKRQAQS PSGVSSEVEV LKALKSLFEH HKALDEKVRE RLRAALERVT TLEEQLAGAH QQVSALQQGA GVRDGAAEEE GTVELGPKRL WKEDTGRVEE LQELLEKQNF ELSQARERLV TLTTTVTELE EDLGTARRDL IKSEELSSKH QRDLREALAQ KEDMEERITT LEKRYLAAQR EATSIHDLND KLENELANKE SLHRQCEEKA RHLQELLEVA EQKLQQTMRK AETLPEVEAE LAQRIAALTK AEERHGNIEE HLRQLEGQLE EKNQELARTA VQVRQREKMN EDHNKRLSDT VDRLLSESNE RLQLHLKERM AALEEKNTLI QELESSQRQI EEQHHHKGRL SEEIEKLRQE VDQLKGRGGP FVDGVHSRSH MGSAADVRFS LGTTTHAPPG VHRRYSALRE ESAKLALPLT VTLRSPTWMR MSQGVCCNLE YHSSGTLCGS SGPLPVPEMI QEEKESTELR AEEIETRVTS GSMEALNLKQ LRKRGSIPTS LTALSLASAS PPLSGRSTPK LTSRSAAQDL DRMGVMTLPS DLRKHRRKLL SPVSREENRE DKATIKCETS PPSSPRTLRL EKLGHPALSQ EEGKSALEDQ GSNPSSSNSS QDSLHKGAKR KGIKSSIGRL FGKKEKGRLI QLSRDGATGH VLLTDSEFSM QEPMVPAKLG TQAEKDRRLK KKHQLLEDAR RKGMPFAQWD GPTVVSWLEL WVGMPAWYVA ACRANVKSGA IMSALSDTEI QREIGISNAL HRLKLRLAIQ EMVSLTSPSA PPTSRTSSGN VWVTHEEMET LETSTKTDSE EGSWAQTLAY GDMNHEWIGN EWLPSLGLPQ YRSYFMECLV DARMLDHLTK KDLRVHLKMV DSFHRTSLQY GIMCLKRLNY DRKELEKRRE ESQHEIKDVL VWTNDQVVHW VQSIGLRDYA GNLHESGVHG ALLALDENFD HNTLALILQI PTQNTQARQV MEREFNNLLA LGTDRKLDDG DDKVFRRAPS WRKRFRPREH HGRGGMLSAS AETLPAGFRV STLGTLQPPP APPKKIMPEA HSHYLYGHML SAFRD
Explore Liprin-alpha-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets